Synergic Fabrication of Naringin Molecule into Polymeric Nanoparticles for the Treatment and Nursing Care of Lung Cancer Therapy

Lung cancer is the third most common cause of death and the main factor of cancer-related deaths in both males and females in the United States to the rest of the world. Diagnosis at an important level is associated with high mortality in the population of cases. Herein, we present a very easy and cost-effective method that incorporates drugs reconstruction, tumor-specific targeting supramolecular nanoassembly, and therapeutically to overcome the different challenges raised by the distribution of the pharmaceutical potential anticancer drug Naringin. On covalent conjugations of hydrophobic linoleic acid by hydroxyl group, the Naringin prodrugs were skilled in impulsively nanoassembly into extremely steady nanoparticles size (similar to 100 nm). Electron microscopic techniques have verified the newly synthesized morphology of Naringin-NPs. The anticancer properties of Naringin and Naringin-NPs against A549 and HEL-299 (lung carcinoma) cancer cell lines have been evaluated after successful synthesis. Other research, such as dual staining acridine orange/ethidium bromide, Hoechst 33,344 and flow cytometry study on the apoptosis mechanisms have shown that proliferation in lung cancer cells is associated with apoptosis. Compared to Naringin, Naringin-NPs demonstrate excellent biocompatibility, this study clarified the Naringin-NPs as a healthy and positive lung cancer treatment and care chemotherapeutics technique and deserve further clinical evaluations. [GRAPHICS]